Clinical and Translational Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2021-04-03 148c69cbm40暂无昵称

审稿速度:2.0 | 投稿命中率:25.0
经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online

237 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2024-12-20 1250080bm96暂无昵称来自北京

偏重的研究方向：肿瘤
经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10

23 0

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2024-08-08 科研小混子来自广东省

审稿速度:1.0 | 投稿命中率:75.0
经验分享：2024-4-17 投稿，under going checking 1周；
2024-4-23 Uder Review;
2024-5-6 Pending recommendation, 1周；
2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天；
2024-7-1 Revison submit, under going checking 1周;
2024-7-8 Uder Review;
2024-7-14 Pending recommendation, 4天；
2024-7-18 Minor review, 第三个审稿人还有个小问题；
2024-7-20 Revison submit；
2024-7-23 Accept

62 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2025-01-13 2122015030 来自陕西省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学
经验分享：Issue Online: 10 January 2025
Version of Record online: 10 January 2025（接收后约20天online）
Manuscript accepted: 22 December 2024
Manuscript revised: 09 December 2024
Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见)
Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答)
Need Revision: 07 October 2024(一审1个月)
Manuscript received: 05 September 2024

整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下
APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！

19 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2025-03-08 ZF2012ZF 来自浙江省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：速度挺快投稿到接受 4 个月

15 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2024-09-26 ms3000001344629820 来自陕西省

投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑

49 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2024-11-17 ms9000001856552545 来自广东省

转letter

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2023-11-16 ms2000002007484521 来自北京

查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。

105 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2025-02-28 ms3000000527522156 来自上海

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：医学转化
经验分享：在等

11 0

[GetPortalCommentsPageByObjectIdResponse(id=953692, encodeId=8aea953692bb, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一次投稿没有送外审被编辑直接拒稿但是副编辑给了修改为letter重新投的机会于是修改为letter后重新投稿送外审一审一个月左右小修修回后三天左右接收很快online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2bf35329265, createdName=148c69cbm40暂无昵称, createdTime=Sat Apr 03 23:54:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2219057, encodeId=d53d221905e84, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2024-4-17 投稿，under going checking 1周； 2024-4-23 Uder Review; 2024-5-6 Pending recommendation, 1周； 2024-5-12 Major Review, 三个审稿人，20个问题，补实验较少，给的70天； 2024-7-1 Revison submit, under going checking 1周; 2024-7-8 Uder Review; 2024-7-14 Pending recommendation, 4天； 2024-7-18 Minor review, 第三个审稿人还有个小问题； 2024-7-20 Revison submit； 2024-7-23 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12916166791, createdName=科研小混子, createdTime=Thu Aug 08 09:03:13 CST 2024, time=2024-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2255223, encodeId=863c2255223e3, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：速度挺快投稿到接受 4 个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b13f1619698, createdName=ZF2012ZF, createdTime=Sat Mar 08 16:13:50 CST 2025, time=2025-03-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2254064, encodeId=7fad225406451, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学转化 经验分享：在等, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79ff8254449, createdName=ms3000000527522156, createdTime=Fri Feb 28 22:40:00 CST 2025, time=2025-02-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达)]

2024-12-18 1811fd99f7m 来自佛罗里达

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：乳腺癌
经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。

39 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务